FRA3B and other common fragile sites: the weakest links

[1]  F. Welch,et al.  Causes and Consequences , 2017, Nature.

[2]  D. Beer,et al.  Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells , 2002, Genes, chromosomes & cancer.

[3]  J. Rowley,et al.  Chromosome translocations: dangerous liaisons revisited , 2001, Nature Reviews Cancer.

[4]  A. Brenner,et al.  WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. , 2001, Cancer research.

[5]  K. Mimori,et al.  Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma. , 2001, Cancer research.

[6]  D J Porteous,et al.  WWOX: A candidate tumor suppressor gene involved in multiple tumor types , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Zucman‐Rossi,et al.  Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma , 2001, Oncogene.

[8]  C. Croce,et al.  The tumor spectrum in FHIT-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Rosato,et al.  Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. , 2001, Cancer research.

[10]  D. Venzon,et al.  Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. , 2001, Cancer research.

[11]  R. Richards.  Fragile and unstable chromosomes in cancer: causes and consequences. , 2001, Trends in genetics : TIG.

[12]  W. Miller,et al.  Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Minna,et al.  Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  C. Croce,et al.  FHIT gene therapy prevents tumor development in Fhit-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Heath,et al.  Hyaluronidase Induction of a WW Domain-containing Oxidoreductase That Enhances Tumor Necrosis Factor Cytotoxicity* , 2001, The Journal of Biological Chemistry.

[16]  W. Hong,et al.  Loss of Fhit expression is a predictor of poor outcome in tongue cancer. , 2001, Cancer research.

[17]  C. Croce,et al.  Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. , 2001, Cancer research.

[18]  C. Brenner,et al.  The nitrilase superfamily: classification, structure and function , 2001, Genome Biology.

[19]  G. Klein,et al.  Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors. , 2000, Cancer research.

[20]  L. Roberts,et al.  The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. , 2000, Genomics.

[21]  F. X. Bosch,et al.  Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  K. Mimori,et al.  Characterization of the human TESTIN gene localized in the FRA7G region at 7q31.2. , 2000, Genomics.

[23]  R. Richards,et al.  Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. , 2000, Human molecular genetics.

[24]  Stephen W. Scherer,et al.  Replication Delay along FRA7H, a Common Fragile Site on Human Chromosome 7, Leads to Chromosomal Instability , 2000, Molecular and Cellular Biology.

[25]  K. Huebner,et al.  Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. , 2000, Cancer research.

[26]  A. McLennan,et al.  The Fhit tumor suppressor protein regulates the intracellular concentration of diadenosine triphosphate but not diadenosine tetraphosphate. , 2000, Cancer research.

[27]  A. Bednarek,et al.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. , 2000, Cancer research.

[28]  J. Sgouros,et al.  A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. , 2000, Cancer research.

[29]  R. Richards,et al.  Chromosomal fragile site FRA16D and DNA instability in cancer. , 2000, Cancer research.

[30]  R. Hruban,et al.  Genomic FHIT analysis in RER+ and RER− adenocarcinomas of the pancreas , 2000, Genes, chromosomes & cancer.

[31]  C. Croce,et al.  Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. , 2000, Cancer research.

[32]  Kathleen R. Cho,et al.  Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. , 2000, Journal of the National Cancer Institute.

[33]  K. Huebner,et al.  The histidine triad superfamily of nucleotide‐binding proteins , 1999, Journal of cellular physiology.

[34]  F. Khuri,et al.  Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. , 1999, Cancer research.

[35]  L. D. Barnes,et al.  The Tumor Suppressor Protein Fhit , 1999, The Journal of Biological Chemistry.

[36]  C. Croce,et al.  The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Minna,et al.  Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. , 1999, Cancer research.

[38]  C. Croce,et al.  Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  O. Kallioniemi,et al.  Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. , 1999, Cancer research.

[40]  George Reid,et al.  Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines , 1999, Oncogene.

[41]  Haojie Huang,et al.  Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer , 1999, Genes, chromosomes & cancer.

[42]  J. Yokota,et al.  Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. , 1998, Cancer research.

[43]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[44]  Y. Pekarsky,et al.  The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells. , 1998, Cancer research.

[45]  D. Beer,et al.  The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. , 1998, Cancer research.

[46]  F. Toledo,et al.  A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. , 1998, Molecular cell.

[47]  Y. Pekarsky,et al.  Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Scherer,et al.  Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  L. Liotta,et al.  Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. , 1998, Cancer research.

[50]  L. D. Barnes,et al.  Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Espinosa,et al.  Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. , 1998, Human molecular genetics.

[52]  F. Kaye,et al.  Protein expression and functional analysis of the FHIT gene in human tumor cells. , 1998, Journal of the National Cancer Institute.

[53]  C. Croce,et al.  Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Beer,et al.  Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas , 1997, Oncogene.

[56]  J. Samet,et al.  Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.

[57]  J S Lee,et al.  Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.

[58]  C. Croce,et al.  Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. , 1997, Cancer research.

[59]  J. Roth,et al.  Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. , 1996, Cancer gene therapy.

[60]  L. D. Barnes,et al.  Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. , 1996, Biochemistry.

[61]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[62]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[63]  S. Ban,et al.  Effect of radiation and cigarette smoking on expression of FUdR-inducible common fragile sites in human peripheral lymphocytes. , 1995, Mutation research.

[64]  J. Testa,et al.  Determination of the specificity of aphidicolin-induced breakage of the human 3p14.2 fragile site. , 1993, Genomics.

[65]  P. Sparén,et al.  Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden , 1993, International journal of cancer.

[66]  H. Aburatani,et al.  Clinical and Genetic Studies of Renal Cell Carcinomas in a Family with a Constitutional Chromosome 3; 8 Translocation: Genetics of Familial Renal Carcinoma , 1993, Annals of Internal Medicine.

[67]  S. Ljunghall,et al.  Serum osteocalcin concentrations in patients with multiple myeloma — correlation with disease stage and survival , 1992, Journal of internal medicine.

[68]  R. Espinosa,et al.  Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[69]  T. Glover,et al.  Chromosome breakage and recombination at fragile sites. , 1988, American journal of human genetics.

[70]  C. Croce.  Role of chromosome translocations in human neoplasia , 1987, Cell.

[71]  J. Yunis,et al.  Constitutive fragile sites and cancer. , 1984, Science.

[72]  S. Jacobs,et al.  Hereditary renal-cell carcinoma associated with a chromosomal translocation. , 1979, The New England journal of medicine.

[73]  A. Knudson,et al.  Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[74]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[75]  富澤 由雄.  Clinicopathological significance of fhit protein expression in stage 1 non-small cell lung carcinoma , 2001 .

[76]  B. Agnarsson,et al.  Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. , 2001, Cancer detection and prevention.

[77]  T. Enomoto,et al.  FHIT alterations in cancerous and non‐cancerous cervical epithelium , 2000, International journal of cancer.

[78]  C. Croce,et al.  Muir-Torre-like syndrome in Fhit-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Y. Pekarsky,et al.  Role of FHIT in human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  G. Karpen,et al.  Fragile sites in human chromosomes as regions of late-replicating DNA , 1987 .